March 7, 2002
Global Managing Partner
North American Managing Partner
Take a Strategic Viewpoint
What is the history of your organization’s involvement in life sciences?
Lacey & Spann: Accenture has been working in the biotech market for more than a decade, both with large pharmaceutical companies and smaller biotech organizations.
What is your vision for the development of the life sciences market?
Lacey & Spann: Our vision is to help the pharmaceutical and biotech industries bring better healthcare products to market more quickly, ultimately changing the way the world works and lives. We’re working with clients around the globe to help pharmaceutical and healthcare companies leverage the new economy—the bioeconomy—to reinvent business models.
What are the key organizational assets you’ve developed to serve this community?
Lacey & Spann: Accenture currently has approximately 2,000 professionals located around the globe who serve pharmaceutical, medical device and biotechnology companies. We believe our No. 1 key organizational asset is our people—and the credentials of our professionals are remarkable: a former CEO of a biotech company; several Ph.D. degree-holders in bioinformatics and IT/technology; several Ph.D. and M.B.A. degree-holders; a number of professionals from drug discovery and biotechnology organizations; and a former FDA chief of staff. Secondly, we have the global resources and a collaborative network of businesses and capabilities to deliver innovative solutions for our clients.
What products and services does your company provide to the life sciences market?
Lacey & Spann: Accenture actively supports the pharmaceutical industry, creating new businesses, markets, and investments. We are working with today’s and tomorrow’s leaders to identify opportunities for value creation and to drive these through to the realization of that value.
Specifically, our industry professionals work with pharmaceutical companies to create value in areas such as strategy development, research and development, finance, manufacturing, logistics, information technology, marketing, sales, and human resources. Accenture has helped develop and implement strategies for more than 90 percent of the Fortune Global 500 pharmaceutical companies. These companies are responsible for 81 percent of the top 100 selling drugs.
What new products and services do you have in development?
Lacey & Spann: This market is constantly changing, and we believe it is critical to be ahead of the curve and anticipate the future. As an example, we are working with leading industry solution providers to develop a comprehensive Web-enabled regulatory compliance capability, and developing an Internet-based clinical trial service for pharmaceutical and biotech companies.
Return to main index page.